You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 悦康藥業高開11% 與病原所合作開發廣譜冠狀病毒膜融合抑制劑多肽藥物
格隆匯 01-10 09:31
格隆匯1月10日丨 悦康藥業(688658.SH)高開11.38%,報31.8元,總市值143億元。悦康藥業1月9日發佈晚間公吿,,公司為進一步履行企業社會責任,落實企業創新升級以及圍繞優勢適應症領域佈局創新藥的發展戰略,基於目前新冠疫情下迫切的臨牀藥物需求,依託公司強大的研發實力、科研成果轉化能力以及中國醫學科學院病原生物學研究所(簡稱“病原所”或“合作方”)強大的科研實力,與中國醫學科學院病原生物學研究所(病原所)簽署《技術轉讓(專利權)合同》,合作開發針對新型冠狀病毒肺炎的廣譜冠狀病毒膜融合抑制劑多肽藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account